Threonine-205 in the F Helix of P450 2B1 Contributes to Androgen 16β-Hydroxylation Activity and Mechanism-Based Inactivation
- Department of Pharmacology, University of Michigan (H.L., P.F.H.), and Department of Anesthesiology, Veteran Affairs Health Service (H.Z., L.W.), Ann Arbor, Michigan
- Address correspondence to:
Dr. Paul F. Hollenberg, Department of Pharmacology, MSRB III, 1150 West Medical Center Dr., Ann Arbor, MI 48109-0632. E-mail: phollen{at}umich.edu
Abstract
Four mutants of Thr-205 in cytochrome P450 2B1 were constructed and expressed in Escherichia coli. The Ser-, Ala-, and Val-mutants displayed stable reduced CO difference spectra and were able to metabolize 7-ethoxy-4-(trifluoromethyl)coumarin, testosterone, androstenedione, and benzphetamine. The Arg-mutant displayed an unstable reduced CO difference spectrum at 450 nm, was concomitantly converted to a denatured form with a peak at 422 nm, and showed no catalytic activity with any of the four substrates tested. The Ser-mutant displayed activity and metabolite profiles for testosterone and androstenedione similar to those of the wild-type P450 2B1 (WT). Substitution of Thr-205 with Ala or Val markedly suppressed the 16β-hydroxylation activity but exhibited little effect on the 16α-hydroxylation activity for testosterone and androstenedione. Because 16β-hydroxylation activity of androgens is a specific P450 2B subfamily marker and residue 205 is located in the F helix, which forms the ceiling of the active site, we postulate that the γ-hydroxyl side chain of Thr may play an important role in directing the 16β-face of testosterone and androstenedione toward the active site. Surprisingly, the Val-mutant retained full activity for benzphetamine demethylation. When mechanism-based inactivators for P450 2B1 were used to evaluate the susceptibility to inactivation, the Val-mutant was resistant to inactivation by 17α-ethynylestradiol and less sensitive to inactivation by 2-ethynylnaphthalene compared with the WT enzyme. Our results demonstrate the importance of Thr-205 in determining substrate specificity and product formation as well as in influencing the susceptibility of P450 2B1 to mechanism-based inactivators.
Footnotes
-
This work was supported in part by National Institutes of Health Grant CA-16954 (to P.F.H.) and VA Merit Review Grant 35533 (to L.W.).
-
DOI: 10.1124/jpet.103.050260.
-
ABBREVIATIONS: P450, cytochrome P450; EFC, 7-ethoxy-4-(trifluoromethyl)coumarin; 2EN, 2-ethynylnaphthalene; 17EE, 17α-ethynylestradiol; DLPC, dilauroyl-l-α-phosphatidylcholine; WT, wild-type P450 2B1 expressed in E. coli.
-
- Received February 14, 2003.
- Accepted April 16, 2003.
- The American Society for Pharmacology and Experimental Therapeutics



